Cholix toxin (Cholix) from Vibrio cholerae is a potent virulence factor exhibiting ADP-ribosyltransferase activity on eukaryotic elongation factor 2 (eEF2) of host cells, resulting in the inhibition of protein synthesis. Administration of Cholix or its homologue Pseudomonas exotoxin A (PEA) to mice causes lethal hepatocyte damage. In this study, we demonstrate cytotoxicity of Cholix on human hepatocytes in the presence of tumor necrosis factor a (TNF-a), which has been reported to play a fatal role in PEA administered to mice. Compared with incubating HepG2 cells with Cholix alone, co-treatment with TNF-a and Cholix (TNF-a/Cholix) significantly enhanced the activation of caspases, cytochrome c release from mitochondria into cytoplasm, and poly-ADP-ribose polymerase (PARP) cleavage, while incubation with TNF-a alone or co-treatment with TNF-a/catalytically inactive Cholix did not. In the early stage of cell death, Cholix increased phosphorylation of mitogenactivated protein kinases (e.g., p38, ERK, JNK) and Akt, which was not affected by TNF-a alone. MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-a/Cholix. Protein kinase inhibitor Go6976 suppressed JNK phosphorylation and PARP cleavage by TNF-a/Cholix. In contrast, PKC activator PMA in the absence of TNF-a promoted Cholix-induced PARP cleavage. Reactive oxygen species (ROS) inhibitor, N-acetyl cysteine (NAC), suppressed TNF-a/Cholixinduced JNK and ERK phosphorylation, resulting in inhibition of PARP cleavage. These data suggest that ROS and JNK pathways are important mediators of TNF-a/Cholix-induced HepG2 cell death.
cholix gene was present in 47% of non-O1/non-O139 strains and 16% of O1/O139 strains in V. cholerae isolated in coastal waters of southern California (Purdy et al., 2010) . In another study, 27% of non-O1/non-O139 strains possessed cholix genes, which encoded toxins that varied in cytotoxicity, while O1 or O139 strains did not possess the gene (Awasthi et al., 2013) . Cholix is a 70-kDa protein toxin that translocates into cells by receptor-mediated endocytosis (Jorgensen et al., 2008) . It was identified as a novel virulence factor that catalyzes ADP-ribosylation of eukaryotic elongation factor 2 (eEF2). Cholix belongs to a group of eEF2 ADP-ribosylating toxins such as diphtheria toxin and Pseudomonas exotoxin A (PEA) from, respectively, Corynebacterium diphtheriae and Pseudomonas aeruginosa. These toxins specifically ADPribosylate diphthamide synthesized from a histidine residue by the diphthamide biosynthesis pathway, followed by inhibition of protein synthesis in host cells (Liu et al., 2004; Roy et al., 2010) . Cholix exhibits significant homology to PEA, with a primary structural identity of about 35%. Previous studies have shown that PEA requires proteolytic cleavage by Furin, a Ca 2þ -dependent serine protease, for induction of cytotoxic activity (Chiron et al., 1997; Gu et al., 1996; Inocencio et al., 1994) . Furin cleaves the consensus sequence -Arg-X-Lys/ArgArg-(RXK/RR) (Hosaka et al., 1991) . From crystal structure analysis, Cholix has a furin cleavage site at a translocation domain (domain II, 265-386) (Jorgensen et al., 2008) . We confirmed in HeLa cells that activation of Cholix required furin activity based on effects of a furin inhibitor (data not shown). Our previous data indicated that both Cholix and PEA induced caspase-dependent apoptosis in HeLa cells (Ogura et al., 2011) . PEA caused severe liver damage in mice (Iglewski et al., 1977) . PEA-induced liver injury in mice involved T celldependent Tumor necrosis factor a (TNF-a) production by Kupffer cells, which was mediated by TNF receptors TNFR1 and TNFR2 expressed in parenchyma, but not in leukocytes (Schumann et al., 1998 (Schumann et al., , 2000 .
TNF-a, mainly produced by macrophages, contributes to a wide spectrum of human diseases and plays critical roles in inflammation and immunity (Parameswaran and Patial, 2010) . TNF-a triggers apoptosis, necrosis, and survival signals through binding two different cell surface receptors, TNFR1 and TNFR2. Multiple experimental approaches have revealed that TNFR1 initiates the majority of TNF's biological activities (Chen and Goeddel, 2002) . In TNFR1-mediated apoptosis, TNFR1-associated death domain protein (TRADD) recruits receptor-interacting protein 1 (RIP1) and Fas-associated death domain protein (FADD), leading to activation of caspases, followed by apoptosis (Baud and Karin, 2001; Croft et al., 2012) . Survival transcription pathways regulated by NF-jB in turn are induced by recruitment of TNF-receptor-associated factor 2 (TRAF2) and RIP by TRADD (Devin et al., 2001; Zhang et al., 2000) . In addition to necrosis, TNF-a can induce programmed necrosis (necroptosis), which is initiated with deubiquitination of RIP1, destabilizing the TRADD-RIP1-FADD complex, and subsequent formation of complexes containing RIP1, RIP3, and caspase-8 (Cho et al., 2009; Degterev et al., 2005) .
In Cholix-treated mice, inflammation and coagulation necrosis were observed in liver (Awasthi et al., 2013) . However, the mechanism of Cholix-induced hepatocyte death is unknown. In this report, we show that the pathways responsible for TNF-a-enhanced, Cholix-induced HepG2 cell death involves reactive oxygen species (ROS) and MAPK-dependent reactions.
MATERIALS AND METHODS

Preparation of Cholix Toxin
Cholix and its catalytically inactive mutant Cholix(E581A) were prepared as described in a previous report (Ogura et al., 2011) . Briefly, pGEX-6P-1/Cholix or Cholix(E581A) plasmids were transfected into E. coli strain BL21(DE3). After induction with 0.5 mM IPTG (Wako Pure Chemical Industries) at room temperature overnight, expressed recombinant GST-tagged Cholix or Cholix(E581A) was applied to Glutathione Sepharose 4B (GE Healthcare). After washing the beads with phosphate-buffered saline (PBS) and digestion by PreScission Protease (GE Healthcare) at 4 C overnight, the purified Cholix proteins were isolated from a flow-through fraction.
Cell Culture and Gene Silencing
HepG2 cells were maintained in Eagle's minimal essential medium (EMEM) (Sigma Aldrich), supplemented with 10% heatinactivated fetal bovine serum, 100 U/ml penicillin, 100 lg/ml streptomycin (FBS-PCSM) and 1 mM sodium pyruvate (Sigma Aldrich). THP-1 cells were cultured in RPMI-1640 medium (Sigma Aldrich), supplemented with FBS-PCSM. Immortalized human hepatocytes, which were immortalized by transfection with the HCV core genomic region from genotype 1a (Ray et al., 2000) , were a gift from Tatsuro Kanda (Chiba University), and cultured in RPMI-1640 (Wako Pure Chemical Industries) supplemented with FBS-PCSM. Non-targeting control (NC) siRNA was purchased from Sigma Aldrich. TNFR1 siRNA was synthesized according to a previous report (5 0 -CAA AGG AAC CUA CUU GUA CUU-3 0 ) (Cho et al., 2008) . HepG2 cells (2 Â 10 5 cells) in a 24-well dish were cultivated overnight in EMEM containing 10% FBS and 1 mM sodium pyruvate and transfected for 48 h with the indicated siRNA (100 nM) using DharmaFECT 4 Transfection Reagent (Dharmacon) in OPTI-MEM I reduced serum medium (GIBCO/ Invitrogen), according to the protocol of the manufacturer. Transfection efficiency and effect were evaluated by Western blotting using the indicated antibodies.
Double Chamber Cell Culture System
Briefly, HepG2 cells (2 Â 10 5 cells/well) were seeded in lower wells and PMA-differentiated THP-1 cells (2 Â 10 5 cells/well)
were cultured in the upper chamber on PET-track-etched membrane (0.4 lM) (BD Bioscience). The toxins (10 lg/ml) were added to the upper or lower chamber medium for 12 h at 37 C, and then cell lysates were prepared for Western blot analysis.
Reagents
A general caspase inhibitor (Z-VAD-FMK) was purchased from BD Biosciences, p38 inhibitor SB2003580 
Western Blot Analysis
Mouse livers were homogenized by Multi-Beads Shocker (Yasuikikai) in RIPA buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 140 mM NaCl). After centrifugation, supernatants were utilized for Western blot analysis. Total cell lysate or cytosolic fraction of the cell line was obtained according to previous reports (Chen et al., 2007; Morinaga et al., 2008) . HRP-bound protein bands were detected by Super Signal West Pico mixture (Thermo Scientific) and visualized by Las-1000 (Fuji Film). 
RNA Isolation and RT-PCR
Detection of ATP Levels
For measurement of ATP level in HepG2 cells, we used Luminescent ATP Detection Assay Kit (Abcam) according to the protocol of the manufacturer. Briefly, cells were incubated with wild-type Cholix or Cholix(E581A) mutant in the presence or absence of TNF-a for 18 h. ATP in the cell lysates was measured by luciferase activity using the GloMAX-Multi Detection System (Promega).
RESULTS
Administration of Cholix to Mice Results in Hepatic Damage
We first examined the effect of Cholix in mice. Intraperitoneal injection of Cholix, but not catalytically inactive mutant Cholix(E581A), resulted in death within 24 h. We observed a marked decrease in Periodic acid-Schiff (PAS)-positive hepatocytes in Cholix-injected mice ( Figure 1A -d, -e, and -f), indicating that glycogen-positive normal hepatocytes were damaged, as compared with control PBS or mutant Cholix-treated mice. In agreement with a previous report (Awasthi et al., 2013) , we also found degenerated destructive and hemorrhagic lesions with apoptotic and inflammatory cells especially at the liver zone between Glisson's sheath and central vein by PAS and HE staining in Cholix-injected mice ( Figure 1A -d, -e, and -f) compared with control PBS ( Figure 1A -a, -b, and -c) or mutant Cholix-treated mice ( Figure 1A -g, -h, and -i). These histological features reveal that Cholix causes lethality with severe liver damage and hepatocyte death. We next investigated the liver injury in Cholixinjected mice in a time-dependent manner. The liver lysate of Cholix-injected mice showed cleavage of poly (ADP-ribose) polymerase (PARP), a marker of apoptosis, after 18 h, but PBS or the mutant Cholix(E581A) did not ( Figure 1B ). Furthermore, we assessed serum alanine transaminase (ALT) to determine liver damage. As shown in Figure 1C , ALT was significantly increased in Cholix-, but not mutant Cholix(E581A)-, injected mice after 18 h. These results indicated that Cholix is a lethal factor causing liver injury.
Effect of TNF-a on Cholix-Induced Cell Death
Previous studies showed that PEA-induced liver damage involved TNF-a production by Kupffer cells (Schumann et al., 1998 (Schumann et al., , 2000 . We investigated the effect of TNF-a on Cholix-induced cytotoxicity in various cells in the presence or absence of TNF-a for 24 h ( Figure 2A and Supplementary Figure 1 ). In THP-1 cells, TNF-a, but not Cholix, decreased the cell viability (Supplementary Figure 1) . In HepG2 cells, Cholix slightly decreased cell viability. TNF-a treatment alone did not affect HepG2 cell viability. Co-treatment of cells with TNF-a/Cholix dramatically decreased viability (20%-40%) ( Figure 2A ). Consistent with cell viability data, in HepG2 cells, TNF-a/Cholix, but not TNF-a alone or TNF-a/Cholix(E581A), significantly decreased cellular ATP levels ( Figure 2B ). To explore the mechanism of Cholix-induced cell death in HepG2 cells, we investigated the time dependence of PARP cleavage and caspase activation ( Figure 2C and Supplementary Figure 2C ). In the absence of TNF-a after 18-24 h treatment, Cholix induced activation of caspase (e.g., caspase-3, -7, -8, -9), PARP cleavage, and cytochrome c release. Treatment of cells with TNF-a/Cholix showed that compared with Cholix alone, caspase activation, PARP cleavage, and cytochrome c release were observed at early time points (12 h) and increased at 12-24 h. Treatment of cells with mutant Cholix(E581A) or TNF-a/Cholix(E581A) did not induce these signals. These data suggested that addition of TNF-a accelerates and enhances apoptotic signals induced by Cholix.
Effects of Caspase and Akt Inhibitors on HepG2 Apoptosis and Necrosis
We next examined effects of a general caspase inhibitor Z-VADFmk on TNF-a/Cholix-induced cell death. Pretreatment with a general caspase inhibitor Z-VAD-Fmk significantly suppressed TNF-a/Cholix-induced activation of caspases-3, -7, and -8, and PARP cleavage ( Figure 3A ). We next investigated cell viability with or without general caspase inhibitor Z-VAD-Fmk and/or necrosis inhibitor Necrostain-1. Cholix/TNF-a-induced decrease in cell viability was dramatically reversed by both Necrostatin-1 and Z-VAD-Fmk, but not by Z-VAD-Fmk alone or Necrostain-1 alone ( Figure 3B ). These data indicated that Cholix-mediated HepG2 cell death is enhanced by TNF-a, and involves both caspase-and necrosis-dependent pathways. These inhibitors partially reversed the loss of cell viability ( Figure 3B ), indicating that HepG2 cell death induced by TNF-a/ Cholix is associated with activation of apoptotic and other pathways. As shown in Figure 3C , Cholix induced Akt phosphorylation, which was increased by TNF-a at the basal level. In the presence of Akt inhibitor Akti, Cholix-induced Akt (Ser473) phosphorylation was significantly suppressed. Under these conditions, in TNF-a/Cholix-treated HepG2 cells, pretreatment with Akti resulted in increased apoptotic signals and decreased cell Mice were injected I.P. with PBS (n¼3), wild-type Cholix (n¼4), and mutant Cholix(E581A) (n¼3). Liver and serum were obtained from each mouse at the indicated times, and then PARP cleavage in the liver (B) and serum ALT level (C) were determined as described in Materials and Methods section. Two representative samples from three mice of each group were utilized for immunoblotting. C, Average and standard deviations of serum ALT levels in each group is shown and significance is *P <0.01. The black bar indicates mutant Cholix(E581A) (MT) and white bar is wild-type Cholix (WT). viability ( Figure 3D and E). However, co-pretreatment with Akti and Z-VAD-Fmk improved cell viability ( Figure 3E ). Further, pretreatment HepG2 cells with JNK inhibitor SP600125 suppressed Cholix-induced Akt phosphorylation (Supplementary Figure 3) . These results suggested that TNF-a/Cholix induces both Akt-and caspase-dependent HepG2 cell death, and Akt phosphorylation is downstream of JNK signaling.
Cholix Induced Apoptosis in HepG2 Cells Co-Cultured With Macrophage-like THP-1 Cells
We next examined whether human macrophages participate in hepatocyte death through TNF-a production. As shown in Figure 4A , the two different types of cells used in the in vitro coculture system, although not directly in contact, indirectly crosstalk via soluble factors produced by each. Monocytic THP-1 cells or macrophage-like THP-1 cells differentiated by PMA were cultured on a semipermeable membrane, and HepG2 cells were seeded in bottom plates. We added the toxins to the apical or basolateral media. The amounts of TNF-a in both membrane and soluble form were increased in macrophage-like THP-1 cells. After 12 h incubation, Cholix-induced PARP cleavage and caspase-6 activation were only detected in HepG2 cells when Cholix was added to the basolateral side and co-cultured with macrophage-like THP-1 cells ( Figure 4B ). In addition, Cholix treatment did not promote PARP cleavage or TNF-a production by the monocytic THP-1 cells or differentiated macrophage-like THP-1. Cholix-induced PARP cleavage in HepG2 cells was not induced by Cholix treatment on the apical side ( Figure 4B) . A previous report showed that TNF receptor 1 (TNFR1) was activated by soluble TNF-a and TNFR2 activation was required for interaction with membrane form of TNF-a (Wajant et al., 2003) . By RT-PCR analysis, we determined the expression levels of TNFR1 and TNFR2. TNFR1, not TNFR2, was the primary form expressed in HepG2 cells and it was expressed in HepG2 cells and not increased by Cholix ( Figure 4C ). We next investigated the effect of TNFR1 on TNF-a/Cholix-induced PARP cleavage. Cholix decreased the amount of TNFR1 in HepG2 cells. Knockdown of TNFR1 by siRNA significantly suppressed TNF-a/Cholix-induced PARP cleavage compared with the control siRNA-transfected cells ( Figure 4D) . Further, the amount of TNFR1 was decreased by Cholix, but not Cholix(E581A). Proteasome inhibitor, lactacystin, inhibited Cholix-decreased TNFR1 expression, which was not affected by lysosome inhibitor, Chloroquine. Thus, TNFR1 was rapidly degraded by proteasomes in the presence of Cholix ( Figure 4E ). These results indicated that soluble TNF-a from macrophage-like THP-1 cells is an essential factor for enhancement of Cholix-induced HepG2 cell death via TNFR1.
Cholix Activates MAPK Pathways in HepG2 Cells
We found that after 8 h incubation, Cholix, but not Cholix(E581A), induced phosphorylation of p38, ERK, and JNK. TNF-a did not significantly affect Cholix-induced phosphorylation of p38, ERK, and JNK, suggesting that a TNF-a signal is not essential for activation of MAPKs ( Figure 5A ). To investigate if Cholix-activated MAPK pathways participated in cell death, we used specific inhibitors (e.g., SB203580, U0126, SP600125), followed by assessment of apoptotic signals. PARP cleavage by TNF-a/Cholix was suppressed by pretreatment with U0126 or SP600125, but not by SB203580 ( Figure 5B ). SP600125 did not affect Cholix-induced phosphorylation of ERK and p38. U0126 suppressed Cholix-induced phosphorylation of JNK, ERK, and p38, which were not altered by SB203580. Thus, Cholix-induced ERK activation is upstream of p38 and JNK activation. These results suggest that MAPKs regulate TNF-a/Cholix-induced apoptosis.
PKC Inhibitor Go6973 Inhibits TNF-a/Cholix-Induced PARP Cleavage
It has been reported that TNF-a-induced cell death is mediated by protein kinase C (PKC) isoforms (Chang and Tepperman, 2001 ). We next investigated the effect of PKC inhibitors (e.g., Bisindolylmaleimide II, Go6976, Go6983) on TNF-a/Cholix-enhanced cell death. These compounds commonly inhibit PKCa and PKCb. Go6976, but not other PKC inhibitors, significantly inhibited TNF-a/Cholix-induced PARP cleavage ( Figure 6A ). Pretreatment of HepG2 cells with phorbol 12-myristate 13-acetate (PMA) in the absence of TNF-a promoted Cholix-induced PARP cleavage . A similar effect was seen with TNF-a/Cholix ( Figure 6B ). Go6976 is known to inhibit PKCa, b and l as well as JAK2, Trk, and Flt3 (Behrens et al., 1999; Grandage et al., 2006; Gschwendt et al., 1996; Martiny-Baron et al., 1993) . PKCl inhibitor, CID755673, did not inhibit Cholix/TNF-a-induced PARP cleavage (Supplementary Figure 1) . Inhibitors of JAK2 (Ruxolitinib), Flt3 (Quizartinib), and Trk (GNF5867) did not suppress Cholix/TNF-a-induced PARP cleavage ( Figure 6C and D) . Previous study has shown that Go6976 prevented JNK activation (Lopez-Bergami et al.,
2005). Pretreatment of HepG2 cells with Go6976 inhibited
Cholix/TNF-a-increased phosphorylation of JNK and ERK, but did not alter p38 phosphorylation. Bisindolylmaleimide II did not affect MAPK phosphorylation increased by Cholix/TNF-a ( Figure 6E ). 25 lM Z-VAD-Fmk, and then incubated for 18 h with 10 lg/ml wild-type Cholix (WT) or mutant Cholix(E581A) (MT) in the presence or absence of TNF-a (25 ng/ml). These cells were lysed with 1ÂSDS sample buffer for immunoblotting with the indicated antibodies. Experiments were repeated three times with similar results.
B, HepG2 cells (1 Â 10 4 cells/well) were treated for 30 min with or without Z-VAD-Fmk (VAD) and/or Necrostatin-1 (Nec-1), and then incubated for 24 h with 10 lg/ml wildtype Cholix (WT), or inactivated mutant Cholix(E581A) (MT) in the absence or presence of 25 ng/ml TNF-a. Cell viability was measured using Cell Counting Kit. Data are the means 6 SD from three separate triplicate experiments. Student's t-test was utilized for comparisons with the untreated cells and significance is *P <0.01. C and D, HepG2 cells (2 Â 10 5 cells/well) were treated for 30 min with or without 5 lM Akti-1/2, and then incubated for 18 h with WT or MT Cholix in the presence of TNF-a (25 ng/ml).
Cells were lysed with 1ÂSDS sample buffer for immunoblotting with the indicated antibodies. Experiments were repeated three times with similar results. E, HepG2 cells (1 Â 10 4 cells/well) were treated for 30 min with or without 5 lM Akti-1/2 and/or Z-VAD-Fmk (VAD), and then incubated for 24 h with 10 lg/ml WT or MT Cholix in the absence or presence of 25 ng/ml TNF-a. Cell viability was measured using Cell Counting Kit. Data are the means 6 SD from three separate triplicate experiments. Student's t-test was utilized for comparisons with the untreated cells and significance is *P<0.01.
ROS Inhibitor Inhibits TNF-a/Cholix-Induced Apoptotic Signals in HepG2 Cells
To examine the effects of ROS on TNF-a/Cholix-induced HepG2 cell death, we used ROS inhibitor N-acetyl cysteine (NAC), followed by assessment of apoptotic signals. After pretreatment of cells with NAC, TNF-a/Cholix-induced caspase-7 and -8 activation and PARP cleavage was suppressed ( Figure 7A ). Next, we investigated the effect of NAC on Cholix-induced MAP kinase activation. NAC suppressed Cholix-mediated phosphorylation of p38, JNK, and Akt, but not ERK ( Figure 7B ). These data suggest that, in HepG2 cells, ROS production by TNF-a/Cholix initiates MAP kinase activation, followed by the induction of apoptotic signals.
Cholix-Induced PARP Cleavage is Not Enhanced by TNF-a in Immortalized Human Hepatocytes
To investigate the effect of Cholix with or without TNF-a on immortalized human hepatocytes, cells were pretreated with NAC, SP600125, Go6976, or Akti, followed by assessment of apoptotic signals ( Figure 8A-D) . Unlike HepG2 cells, TNF-a did not promote Cholix-induced PARP cleavage, which was enhanced by NAC and Akti ( Figure 8A and D) . Further, Cholix suppressed Akt phosphorylation. After pretreatment of cells with SP600125 or Go6976, Cholix-induced PARP cleavage was suppressed as was seen in HepG2 cells. These findings suggest that immortalized human hepatocytes are more sensitive to Cholix compared with HepG2 cells and that Cholix-induced cell death mechanism is different between HepG2 cells and immortalized human hepatocytes. Cholix-induced apoptosis is independent of TNF-a and ROS in immortalized human hepatocytes. Further, Cholix action is regulated in immortalized human hepatocytes by a JNKdependent signaling pathway.
DISCUSSION
We demonstrate here that intraperitoneal injection of Cholix to mice caused a lethal, hemorrhagic inflammation and cytotoxic response in liver within 24 h (Figure 1 ). In Cholix-treated mouse liver, we found PARP cleavage after 18 h and some TUNELpositive cells (Supplementary Figure 2) . The mechanism by which Cholix induced hepatic cell death remains unknown. To date, only one report has shown in vivo cytotoxicity of Cholix (Awasthi et al., 2013) . Cholix exhibits high homology to PEA with a primary structural identity of about 35% (Jorgensen et al., 2008) . It was reported that PEA induced hepatic injury, which is mediated by TNF-a produced by Kupffer cells (Schumann et al., 1998 (Schumann et al., , 2000 . In a rat model, massive necrosis and apoptosis were induced by injection of PEA, while only apoptotic cells were observed at lower dose (Chiu et al., 2009) . As shown in Figure 2 and 8, and a previous report (Ogura et al., 2011) , sensitivity of human cell lines to Cholix was variable. In the presence of TNF-a, Cholix, but not the catalytically inactive mutant Cholix(E581A), induced accelerated cell death in HepG2 cells. Liedtke et al. (2002) reported that human hepatocyte Huh7 cells co-treated with TNF-a and cycloheximide undergo apoptosis, preceded by JNK activation. Cholix-induced PARP cleavage was detected in Huh7 cells (data not shown) and immortalized human hepatocytes in the absence of TNF-a (Figure 8) , similar to the observation in HeLa cells (Ogura et al., 2011) , suggesting that the apoptotic pathway induced by TNF-a/ cycloheximide is different from that activated by Cholix.
In TNF-a/Cholix-treated HepG2 cells, apoptotic signals were activated after a 12-h incubation ( Figure 2C ). Pretreatment with a general caspase inhibitor suppressed TNF-a/Cholix-induced activation of caspase-3 and caspase-8. However, the inhibitor did not completely suppress cytochrome c release and activation of caspase-7 and caspase-9. These findings suggest that TNF-a/Cholix-induced cytochrome c release from mitochondria is caspase-independent, but is followed by caspase-9 and -7 activation. We previously found in HeLa cells that Cholix induced caspase-mediated apoptosis dependent on inflammatory caspases and caspase-8 (Ogura et al., 2011) . As shown in Figure 7 , inhibition of ROS signals by NAC significantly suppressed apoptosis in TNF-a/Cholix-treated HepG2, while NAC did not suppress apoptosis in Cholix-treated human immortalized hepatocytes (Figure 8 ), suggesting that Cholix-induced apoptosis has TNF-a-initiated ROS-and non-ROS-dependent pathways.
It is known that TNF-a is involved in liver injury (Schwabe and Brenner, 2006) . In a co-culture system as shown in Figure 4 , PMA-induced differentiation of the THP-1 monocytic cells to a macrophage-like cells resulted in increased expression of membrane and soluble forms of TNF-a. Cholix did not enhance TNFa production in macrophage-like THP-1 cells. When Cholix was added to the apical side, it was absorbed to THP-1 cells, and, therefore, might not reach HepG2 cells in the bottom chamber. In contrast, addition of Cholix to the basolateral side allowed contact with TNF-a-stimulated HepG2 cells, resulting in enhanced Cholix-induced PARP cleavage and caspase activation. Previous studies showed that PEA-induced TNF-a production in Kupffer cells was activated by T cells (Muhlen et al., 2004; Schumann et al., 1998) . Thus, Cholix did not directly induce TNF-a production by macrophages but acted through signals from other cells to macrophages, resulting in liver injury in vivo.
TNFR1 is the predominant TNF receptor expressed by HepG2 cells. Cholix down-regulated the amount of TNFR1, although TNFR1 mRNA expression was not changed by Cholix. TNF-a-TNFR1 complexes are rapidly endocytosed by cells and then degraded in secondary lysosomes to terminate signaling (Mosselmans et al., 1988) . Another group demonstrated that TNFR1 internalized by adenovirus RIDa/b was degraded through the endosomal/lysosomal pathway (Chin and Horwitz, 2005) . However, TNFR1 expression in TNF-a/Cholix(E581A) mutanttreated cells was similar to that in cells treated with Cholix(E581A) mutant alone. In agreement, in HepG2 cells, complex formation between TNF-a and TNFR1 did not affect TNFR1 expression on the cell surface. Pretreatment of HepG2 cells with a proteasome inhibitor, lactacystin, blocked down-regulation of TNFR1 expression by Cholix, although it was not affected by the lysosome inhibitor chloroquine (Figure 4 ). These data suggest that the Cholix-dependent decrease in TNFR1 expression may occur thorough proteolytic degradation via the proteasome, and not through the lysosome. MAP kinase signal transduction pathways are regulated by p38-MAPK, ERK, JNK, and ERK5. The MAP kinase pathway is involved in cell proliferation, differentiation, migration, senescence, and apoptosis (Sun et al., 2015) . In the absence of TNF-a, Cholix activated the MAPK pathway. W€ atjen et al. (2014) reported in rat hepatocytes (H4IIE), that incubation with mycotoxin beauvericin increased JNK phosphorylation, decreased ERK phosphorylation and resulted in apoptosis. In rat intestinal (IEC-6) cells, TNF-a/cycloheximide-induced apoptosis was caused by ROS production, followed by phosphorylation of JNK and, subsequently, ERK (Jin et al., 2008) . Inhibition of Rac1 signaling by expression of dominant-negative Rac1 decreased TNF-a-induced mitochondrial ROS production (Jin et al., 2008) . In this study, TNF-a/Cholix-induced apoptotic signals were suppressed by specific inhibitors (Figs. 5 and 6 ), which interfered with Cholix-induced phosphorylation of JNK and ERK. PKC-activator, PMA, enhanced Cholix-induced PARP cleavage similar to what was seen by addition of TNF-a. It was reported that, in gastric cancer cells, PMA promoted PKC-dependent JNK activation, followed by induction of apoptosis . In addition, PKC isoforms are involved in JNK activation, which induces apoptosis (Comalada et al., 2003; Garin et al., 2007; Lopez-Bergami and Ronai, 2008) . Although we could not identify the PKC isoforms that regulate JNK activation, our data suggest that PKC regulates JNK activity, which is required for TNF-a/ Cholix-induced apoptosis.
Furthermore, ROS inhibitor NAC pretreatment significantly suppressed apoptotic signals and phosphorylation of p38, JNK, and Akt, but not ERK. We also show here that TNF-a alone did not induce MAPK phosphorylation and HepG2 cell death. hibitors (e.g., Bis II, Go6976, Go6983), 100 nM PMA, 20 lM SB20350, 10 lM Ruxolitinib, 10 lM Quizarnib, 10 lM GNF5867, followed by the incubation for 12 h with 10 lg/ml wild-type (WT) or mutant Cholix (MT) in the presence or absence of TNF-a (25 ng/ml). E, Cells were pretreated for 30 min with the indicated inhibitors and then incubated for 12 h with 10 lg/ml wild-type Cholix (WT) or mutant Cholix (MT) in the presence or absence of TNF-a (25 ng/ml). Then cells were lysed with 1ÂSDS sample buffer for immunoblotting with the indicated antibodies. Experiments were repeated three times with similar results. Quantification of phospho-JNK and phospho-p38 level in HepG2 cells was performed by densitometry (bottom panel). Data are presented as mean 6SD from three experiments and significance is *P<0.05.
Further, TNFR1 knockdown decreased TNF-a/Cholix-induced PARP cleavage. Our data suggest that JNK is a key factor and ROS signals induced by the addition of TNF-a initiates cell death by TNF-a/Cholix, which is in agreement with a previous report; ROS and JNK pathways are important for TNF-a-mediated liver injury (Schwabe and Brenner, 2006) . Thus, TNF-a acts as a key activator in Cholix-induced cell death. Kim et al. (2010) reported that ROS modulator 1 (Romo1) and B-cell lymphoma-extra large are directly associated with TNF-a/cycloheximide-induced ROS production in HeLa cells. TNF-a/Cholix-induced PARP cleavage was not suppressed in Romo1-overexpressing HepG2 cells (data not shown), indicating that Romo1 is not involved in TNF-a/ Cholix-induced apoptosis. In HepG2 cells, PARP cleavage and caspase activation were significantly enhanced by TNF-a/Cholix co-treatment (Figure 2 and Supplementary Figure 1C) . Although a general caspase inhibitor, Z-VAD-Fmk, suppressed activation of caspases, cell viability was still reduced. Akt inhibitor pretreatment showed enhanced TNF-a/Cholix-induced apoptotic pathway. As shown in Figure 3D , TNF-a/Cholix-induced cell death was significantly improved by co-pretreatment with Z-VAD-Fmk and Akt inhibitor, Akti. Our data indicated that Akt activation might be induced by TNF-a/Cholix and is involved in non-apoptotic cell death. Previous reports showed that Akt activation induces necroptosis, a non-apoptotic programmed cell death. McNamara et al. (2013) reported that Akt controls necroptosis through downstream targeting of mammalian Target of Rapamycin complex 1 (mTORC1) in a RIP1-dependent fashion in mouse L929 fibroblasts. In mouse hippocampal HT22 cells, TNF-a/Z-VAD-Fmk co-treatment induced necroptosis, which was preceded by RIP1-RIP3-pAkt assembly (Liu et al., 2014) . Necroptosis has been considered as an alternative cell death mechanism, which is induced when apoptosis is blocked (Degterev et al., 2005) . In addition, a recent study showed that xenoestrogen 4-nonylphenol reactivates ROS-dependent JNK-and AKT/ AMPK/mTOR signaling, which regulates apoptosis, autophagy and necrosis (Duan et al., 2016) . Further, it was reported that JNK activation not only involves necroptosis (Chen et al., 2011; Christofferson et al., 2012) but also necrosis (Ventura et al., 2004) . Our result showed that inhibition of JNK phosphorylation by NAC or SP600125 suppressed TNF-a/Cholix-induced Akt phosphorylation in HepG2 cells, suggesting that Akt was regulated downstream of ROS and JNK, and that pathway might participate in cell death involving apoptosis, necroptosis or necrosis.
In contrast, it is also known that Akt activation protects liver from cell death during various stresses (e.g., acute cold exposure, ischemia/reperfusion injury, cytokine) (Ashare et al., 2007; Harada et al., 2004; Wang et al., 2013) . In agreement with these previous reports, Cholix decreased Akt phosphorylation and Akt inhibitor increased Cholix-induced PARP cleavage in human immortalized hepatocytes, which are highly sensitive to Cholix and more responsive than HepG2 cells. These results indicate that, in human immortalized hepatocytes, Akt protects against Cholix-induced cytotoxicity.
In conclusion, we propose a model of TNF-a/Cholix-induced HepG2 cell death (Figure 9 , left panel). Cholix is activated by Furin and induces eEF2 ADP-ribosylation. This event causes MAPK activation and Akt phosphorylation, followed by induction of apoptosis. In the presence of TNF-a from macrophages, TNF-a binds to TNFR1, and its signal leads to ROS production, and then MAPK activation in the presence of Cholix, but not TNF-a/Cholix(E581A). Inhibition of ROS by NAC suppressed phosphorylation of Akt and JNK. In addition, PKC inhibitor Go6973 suppressed TNF-a-enhanced JNK activation, suggesting that JNK regulates TNF-a/Cholix-induced cell death involving apoptosis, necroptosis or necrosis. On the contrary, in human immortalized hepatocytes (Figure 9 , right panel), Cholix induced eEF2 ADP-ribosylation, followed by down-regulation of Akt phosphorylation. Addition of TNF-a did not affect Cholixinduced apoptosis. Inhibition of Akt activity by Akti or NAC promoted apoptosis by Cholix. Further, Cholix-induced apoptosis was suppressed by inhibition of JNK and PKC. Thus, the Cholixinduced cell death mechanism is different in HepG2 cells and immortalized human hepatocytes. We need further study to clarify this point. Taken together, our data show that TNF-a enhanced Cholix-induced apoptosis via MAPK activation in HepG2 cells.
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